CY1109734T1 - Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης - Google Patents

Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης

Info

Publication number
CY1109734T1
CY1109734T1 CY20101100028T CY101100028T CY1109734T1 CY 1109734 T1 CY1109734 T1 CY 1109734T1 CY 20101100028 T CY20101100028 T CY 20101100028T CY 101100028 T CY101100028 T CY 101100028T CY 1109734 T1 CY1109734 T1 CY 1109734T1
Authority
CY
Cyprus
Prior art keywords
alkyl
halogen
hydrogen
independently hydrogen
hydroxy
Prior art date
Application number
CY20101100028T
Other languages
English (en)
Inventor
Craig P Smith
David E Rampe
Beth Borowsky
Sathapana Kongsamut
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of CY1109734T1 publication Critical patent/CY1109734T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μεθόδους για τη θεραπευτική αντιμετώπιση της σχιζοφρένειας και/ή ανωμαλιών ρύθμισης της γλυκόζης σε έναν ασθενή χρήζοντα αυτής, και περιλαμβάνουν τη χορήγηση στον εν λόγω ασθενή μιας θεραπευτικά αποτελεσματικής ποσότητας μιας ένωσης του τύπου (I) όπου το m είναι 0, 1 ή 2, το n είναι 0, 1 ή 2, το p είναι 0 ή 1, έκαστο R είναι ανεξάρτητα υδρογόνο, αλογόνο, τριφθορομεθύλιο, C1-C6αλκύλιο, C1-C6αλκοξύ, βενζυλοξύ, υδροξύ, νιτρο- ή αμινο-ομάδα, έκαστο R1 είναι ανεξάρτητα υδρογόνο, C1-C6αλκύλιο, C1-C6αλκενύλιο, C1-C6αλκανοΰλιο, αλογόνο, κυανο-ομάδα, -C (O) C1-C6αλκύλιο, -C1-C6αλκυλένιoCN, -C1-C6αλκυλένιοNR'R" όπου τα R' και R" είναι έκαστο ανεξάρτητα υδρογόνο ή C1-C6αλκύλιο, -C1-C6αλκυλένιoOC(Ο)C1-C6αλκύλιο, ή -CH(OH)R4 όπου το R4 είναι υδρογόνο ή C1-C6αλκύλιο, το R2 είναι υδρογόνο, C1-C6αλκύλιο προαιρετικά υποκατεστημένο με αλογόνο, υδροξύ ή βενζυλοξύ, C1-C6αλκενύλιο, C1-C6αλκυνύλιο, -C02C1-C6αλκύλιο, ή -R5-NR' R" όπου το R5 είναι C1-C6αλκυλένιο, C1-C6αλκενυλένιο ή C1-C6αλκυνυλένιο και τα R' και R" είναι έκαστο ανεξάρτητα υδρογόνο, C1-C6αλκύλιο ή εναλλακτικά η ομάδα -NR'R" ως σύνολο είναι 1-πυρρολιδινύλιο, και το R3 είναι υδρογόνο, νιτρο-ομάδα, αμινο-ομάδα, αλογόνο, C1-C6αλκοξύ, υδροξύ ή C1-C6αλκύλιο, ή ένα φαρμακευτικά αποδεκτό άλας αυτής.
CY20101100028T 2004-04-01 2010-01-11 Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης CY1109734T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55845104P 2004-04-01 2004-04-01
EP05732721A EP1734959B1 (en) 2004-04-01 2005-04-01 Compounds for treating schizophrenia and/or glucoregulatory abnormalities

Publications (1)

Publication Number Publication Date
CY1109734T1 true CY1109734T1 (el) 2014-09-10

Family

ID=34978926

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100028T CY1109734T1 (el) 2004-04-01 2010-01-11 Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης

Country Status (26)

Country Link
US (1) US20070129403A1 (el)
EP (2) EP2138176A1 (el)
JP (1) JP2007531730A (el)
KR (1) KR20070010161A (el)
CN (1) CN1946399A (el)
AR (1) AR048197A1 (el)
AT (1) ATE446754T1 (el)
AU (1) AU2005231446A1 (el)
BR (1) BRPI0509512A (el)
CA (1) CA2561162A1 (el)
CL (1) CL2009001605A1 (el)
CY (1) CY1109734T1 (el)
DE (1) DE602005017373D1 (el)
DK (1) DK1734959T3 (el)
DO (1) DOP2005000050A (el)
ES (1) ES2334241T3 (el)
GT (1) GT200500063A (el)
IL (1) IL178168A0 (el)
MX (1) MXPA06011222A (el)
PA (1) PA8628601A1 (el)
PL (1) PL1734959T3 (el)
PT (1) PT1734959E (el)
SI (1) SI1734959T1 (el)
SV (1) SV2006002069A (el)
TW (1) TW200602040A (el)
WO (1) WO2005097122A2 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
CA2665698A1 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
AU2007307638A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010068750A2 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
JP5714572B2 (ja) * 2009-06-03 2015-05-07 マーケット ユニバーシティー 精神障害およびその症状の治療のためのkcnqカリウムチャネル活性の調節方法
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
RU2544852C2 (ru) 2009-10-14 2015-03-20 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
MY165117A (en) 2010-02-26 2018-02-28 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
CN103512972A (zh) * 2013-07-29 2014-01-15 上海交通大学 精神分裂症的生物标志物及其使用方法和应用
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
KR101759122B1 (ko) 2015-08-07 2017-07-18 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물
MX2019002265A (es) 2016-08-24 2019-10-30 Prilenia Therapeutics Dev Ltd Uso de pridopidina para el tratamiento de la disminucion funcional.
CN113840569A (zh) * 2019-03-19 2021-12-24 剑桥认知有限公司 诊断精神病症和推荐用于精神病症的治疗的方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
DE3852335T2 (de) * 1987-04-24 1995-05-11 Hoechst Roussel Pharma N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel.
US5102891A (en) * 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder
ES2174081T3 (es) * 1995-07-27 2002-11-01 Aventis Pharma Inc Uso de n-(pirrol-1-il)piridinaminas sustituidas y no sustituidas como agentes anticonvulsivos.
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
SI1734959T1 (sl) 2010-02-26
EP1734959A2 (en) 2006-12-27
DK1734959T3 (da) 2010-03-08
GT200500063A (es) 2005-10-14
KR20070010161A (ko) 2007-01-22
PL1734959T3 (pl) 2010-03-31
EP1734959B1 (en) 2009-10-28
DOP2005000050A (es) 2005-11-30
CN1946399A (zh) 2007-04-11
CL2009001605A1 (es) 2009-11-27
PA8628601A1 (es) 2006-05-16
ATE446754T1 (de) 2009-11-15
BRPI0509512A (pt) 2007-09-11
JP2007531730A (ja) 2007-11-08
AU2005231446A1 (en) 2005-10-20
MXPA06011222A (es) 2007-01-16
ES2334241T3 (es) 2010-03-08
IL178168A0 (en) 2006-12-31
US20070129403A1 (en) 2007-06-07
PT1734959E (pt) 2009-12-24
AR048197A1 (es) 2006-04-05
SV2006002069A (es) 2006-05-24
TW200602040A (en) 2006-01-16
WO2005097122A2 (en) 2005-10-20
DE602005017373D1 (de) 2009-12-10
WO2005097122A3 (en) 2006-02-02
EP2138176A1 (en) 2009-12-30
CA2561162A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
CY1109734T1 (el) Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης
RU2324684C2 (ru) Пиримидиновые производные
EA200700099A1 (ru) Производные пиридина
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
ATE517882T1 (de) Chinolinderivate
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
EA200801041A1 (ru) Ингибиторы мек и способы их применения
CY1108583T1 (el) Μεθοδος για θεραπεια σοβαρης καρδιακης ανεπαρκειας και φαρμακο για αυτη
EA200501095A1 (ru) Фенилацетамиды и их применение в качестве модуляторов глюкокиназы
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20053748L (no) Pyrrolopyridazinderivater.
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
SE0401342D0 (sv) Therapeutic compounds
EA200700642A1 (ru) Способы лечения эпилептогенеза и эпилепсии
DK2040703T3 (da) Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы